Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Rogalsky

Surgery Coos Bay, OR Medical Doctor

NPI 1184010191 CMS profile 7230458

1900 Woodland Dr, Coos Bay, OR 97420

Open in the dashboard

General payments

$4,005

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derek Rogalsky of Coos Bay, OR is reported in the CMS Open Payments database as having received $4,005 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27 1
2024 General $2,168 11
2023 General $1,728 11
2021 General $71 3
2019 General $11 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Rogalsky
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Derek Rogalsky were reported at $27. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Derek Rogalsky Surgery median Middle half National median
2019 $11 $253 $82–$1,521 $163
2020 $0 $131 $40–$706 $114
2021 $71 $168 $50–$904 $132
2022 $0 $224 $76–$1,218 $149
2023 $1,728 $253 $82–$1,255 $160
2024 $2,168 $279 $90–$1,381 $164
2025 $27 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,273 12 payments
  2. Medical Device Business Services, Inc. $1,425 4 payments
  3. Ethicon US, LLC $143 6 payments
  4. Intuitive Surgical, Inc. $91 3 payments
  5. Heron Therapeutics, Inc. $61 1 payment
  6. Microline Surgical Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,068 9 payments
  2. Food and Beverage $937 18 payments
Products named General payments · program years 2019–2025
  1. ECHELON ENDOPATH $1,452 5 payments
  2. Da Vinci Surgical System $91 3 payments
  3. APONVIE $61 1 payment
  4. Echelon Flex Surgery-Bariatric $51 2 payments
  5. Enseal $27 1 payment
  6. Echelon Flex Endo-Mechanical $24 1 payment
  7. Enseal X1 $14 1 payment
  8. General Therapies $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

633

Median for General Surgery: 59

Drug cost

$50,674

Median for General Surgery: $393

Branded share of claims

20.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 25 $25,437
Ozempic Semaglutide Brand 13 $11,992
Ursodiol Generic 77 $6,104
Sucralfate Generic 14 $2,002
Pantoprazole Sodium Generic 181 $1,621
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 24 $1,536
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 50 $850
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 15 $228
Famotidine Generic 20 $200
Oxycodone Hcl Generic 72 $171

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$162,861

Of which drugs: $472

Medicare patients

407

Average age 71

Services billed

4,177

234 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 35%
Depression 31%
Heart failure 25%
Chronic kidney disease 25%
COPD 25%
Ischemic heart disease 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 26 2,170 $220

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record